Skip to content
DataLookout
Menu

NCT06039696

Pathogenic Metagenomic Next-generation Sequencing to Optimize the Diagnosis of Decompensated Cirrhosis Infection

StatusUnknown
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
  2. Notable Enrollment target: 480 to 850v2 Show 4 more changesShow less
    • Primary completion date: Jun 30, 2021 to Dec 30, 2024
    • Study completion date: Apr 2024 to Mar 30, 2025
    • Secondary endpoints: 5 to 7
    • Study description expanded, about 112 words
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Positive rate of mNGS test in AD patients
Timeframe: at enrolment

Secondary (7)

90-day transplantation-free mortality
Incidence of acute kidney injury (AKI)
Proportion of hospital readmissions due to infections
Proportion of progression to SIRS or sepsis
Consistency with blood culture results
Show 2 moreShow less
Incidence of CMV reactivation
Rate of progression to acute-on-chronic liver failure (ACLF)

Arms and interventions

patients received mNGS test

After enrolment, patients will receive mNGS test.

Sites

1 site in 1 country

  • Nanfang HospitalGuangzhou, Guangdong, China